{"id":8999,"date":"2026-09-02T14:47:18","date_gmt":"2026-09-02T12:47:18","guid":{"rendered":"https:\/\/mumak.me\/?p=8999"},"modified":"2026-09-02T14:58:41","modified_gmt":"2026-09-02T12:58:41","slug":"red-hot-chili-mumak-of-the-week-johnson-johnson-breakout-drawing-closer","status":"publish","type":"post","link":"https:\/\/mumak.me\/en\/portfolio-updates\/company-update\/red-hot-chili-mumak-of-the-week-johnson-johnson-breakout-drawing-closer\/","title":{"rendered":"RED HOT CHILI\u2122 MUMAK of the Week: Johnson & Johnson \u2013 Breakout Drawing Closer?"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Why the stock appears particularly compelling right now<\/h2>
With the RED HOT CHILI\u2122 MUMAK, we highlight every week the company that currently shows the greatest alignment across our five analysis levels:<\/div>
<\/div>
  • Geopolitics<\/strong><\/li>
  • Industry<\/strong><\/li>
  • Fundamentals<\/strong><\/li>
  • News & Market Sentiment<\/strong><\/li>
  • Technical Analysis<\/strong><\/li><\/ul>
    This week, Johnson & Johnson<\/strong> receives this award.<\/div>
    <\/div>
    The company combines robust operational development with a strong position in Innovative Medicine and MedTech<\/strong>. At the same time, the stock is trading immediately below an important technical resistance.<\/div>
    <\/div>
    Particularly compelling at present is the combination of fundamental stability, positive analyst sentiment, and a still-intact medium-term uptrend<\/strong>.<\/div>

    Fundamental Development Remains Robust<\/h3>
    Johnson & Johnson achieved revenue of $25.3 billion<\/strong> in the second quarter, up 6.6%<\/strong> year-over-year. Adjusted earnings per share reached $2.90<\/strong>.<\/div>
    <\/div>
    Following the results, the company also raised its full-year guidance. For 2026, Johnson & Johnson now expects revenue of approximately $101.1 billion<\/strong> at the midpoint of the guidance range and adjusted earnings per share of approximately $11.68<\/strong>.<\/div>
    <\/div>
    Key drugs such as Darzalex, Carvykti, Tremfya, and Spravato<\/strong> as well as the broad product pipeline remain central growth drivers.<\/div>

    UBS Raises Price Target Significantly to $320<\/h3>
    Additional tailwind currently comes from the analyst side.<\/div>
    <\/div>
    UBS raised its price target for Johnson & Johnson from $280 to $320 on September 2 and confirmed its “Buy” rating.<\/strong><\/div>
    <\/div>
    According to MarketScreener, the average analyst consensus remains Outperform<\/strong>, with the median price target at approximately $273.82<\/strong>.<\/div>
    <\/div>
    The significantly higher UBS target underscores the bank’s constructive assessment and lies clearly above the current stock price of approximately $271<\/strong>.<\/div>
    <\/div>
    Thus, in addition to fundamentals and technical analysis, the analysis level News & Market Sentiment<\/strong> also receives additional tailwind.<\/div>

    Technical Analysis: $273\u2013274 Becomes the Key Zone<\/h3>
    At currently approximately $271.19<\/strong>, Johnson & Johnson is once again trading immediately below the resistance at $273.41<\/strong>.<\/div>
    <\/div>
    This area has been tested several times recently and is thus developing into the critical technical level.<\/div>
    <\/div>
    A sustained breakout above $273\u2013274<\/strong> could confirm the existing upward movement and trigger a new impulse.<\/div>
    <\/div>
    Above that, the upper Bollinger Band currently runs at approximately $276.32<\/strong>.<\/div>
    <\/div>
    On the downside, the zone between $262 and $266<\/strong> forms the most important near-term support.<\/div>

    RSI Positive \u2013 MACD Weaker Near-Term<\/h3>
    The RSI (14)<\/strong> currently stands at approximately 59 points<\/strong>.<\/div>
    <\/div>
    Thus, momentum remains constructive without the stock appearing technically overbought yet.<\/div>
    <\/div>
    The MACD<\/strong>, however, shows somewhat less dynamism near-term. The MACD and signal lines have recently converged, while the histogram has turned slightly negative.<\/div>
    <\/div>
    A renewed positive MACD signal together with a breakout above $273\u2013274<\/strong> would significantly improve the overall technical picture once again.<\/div>

    Why Does Johnson & Johnson Receive the RED HOT CHILI\u2122 MUMAK?<\/h3>
    Currently, several constructive factors converge at Johnson & Johnson:<\/div>
    <\/div>
    • revenue growth of 6.6%<\/strong><\/li>
    • raised full-year guidance<\/strong><\/li>
    • strong position in Innovative Medicine and MedTech<\/strong><\/li>
    • broad product pipeline<\/li>
    • UBS price target of $320<\/strong><\/li>
    • intact medium-term uptrend<\/li>
    • RSI above 50<\/strong><\/li>
    • stock immediately before the resistance at $273\u2013274<\/strong><\/li><\/ul>
      Risks remain particularly the increasing biosimilar competition for Stelara<\/strong>, existing legal uncertainties, and the comparatively high valuation.<\/div>

      Core Message<\/h3>
      Johnson & Johnson currently combines robust fundamental development with positive analyst sentiment and a constructive chart picture<\/strong>.<\/div>
      <\/div>
      At approximately $271<\/strong>, the stock stands immediately before the important resistance zone at $273\u2013274<\/strong>.<\/div>
      <\/div>
      A sustained breakout above could confirm the technical upward movement. On the downside, the zone between $262 and $266<\/strong> remains the critical near-term support.<\/div>
      <\/div>
      Additional tailwind comes from the current assessment by UBS<\/strong>: The bank has raised its price target significantly from $280 to $320<\/strong> and confirmed its buy recommendation.<\/div>
      <\/div>
      The combination of operational strength, raised guidance, positive analyst sentiment, and an intact medium-term uptrend<\/strong> makes Johnson & Johnson currently one of the most compelling stocks within our analysis universe.<\/div>
      <\/div>
      Therefore, Johnson & Johnson<\/strong> receives the RED HOT CHILI\u2122 MUMAK<\/strong> award this week. \ud83d\udd25\ud83d\udcc8<\/div>
      <\/div>

      Note<\/h3>
      There can be only one RED HOT CHILI\u2122 MUMAK at any given time.<\/div>
      <\/div>
      The RED HOT CHILI\u2122 MUMAK is an internal award of the MUMAK\u00ae UMBRELLA Strategy. It identifies the company that, at the time of publication, shows the highest alignment across the five MUMAK\u00ae analysis categories within our analysis universe.<\/div>
      <\/div>
      The award does not constitute investment advice nor a buy, hold, or sell recommendation. Capital investments involve risks and may result in the complete loss of invested capital.<\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

      Johnson & Johnson shows operational strength and a constructive chart picture. The resistance at $273\u2013274 now comes into focus.<\/p>\n","protected":false},"author":2,"featured_media":2171,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[151],"tags":[520,360,375,329],"aktie":[],"class_list":["post-8999","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-update","tag-chart-analysis","tag-aktienanalyse","tag-johnson-johnson","tag-pharmaceutical-industry"],"acf":[],"_links":{"self":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts\/8999","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/comments?post=8999"}],"version-history":[{"count":4,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts\/8999\/revisions"}],"predecessor-version":[{"id":9012,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts\/8999\/revisions\/9012"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/media\/2171"}],"wp:attachment":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/media?parent=8999"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/categories?post=8999"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/tags?post=8999"},{"taxonomy":"aktie","embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/aktie?post=8999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}